68.49 0.3 (0.44%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 80.06 ![]() |
1-year : | 93.51 ![]() |
Resists | First : | 68.55 ![]() |
Second : | 80.06 ![]() |
Pivot price | 67.91 ![]() |
|||
Supports | First : | 67.59 ![]() |
Second : | 67.01 |
MAs | MA(5) : | 68.16 ![]() |
MA(20) : | 67.78 ![]() |
MA(100) : | 67.58 ![]() |
MA(250) : | 62.92 ![]() |
|
MACD | MACD : | 0.2 ![]() |
Signal : | 0.1 ![]() |
%K %D | K(14,3) : | 85.3 ![]() |
D(3) : | 81.9 ![]() |
RSI | RSI(14): 67.6 ![]() |
|||
52-week | High : | 69.68 | Low : | 48.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AXNX ] has closed above the upper band by 4.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 68.63 - 68.89 | 68.89 - 69.09 |
Low: | 67.55 - 67.87 | 67.87 - 68.14 |
Close: | 68 - 68.5 | 68.5 - 68.91 |
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Fri, 26 Jul 2024
Janney Montgomery Scott LLC Takes $218,000 Position in Axonics, Inc. (NASDAQ:AXNX) - Defense World
Thu, 25 Jul 2024
Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors - Quantisnow
Wed, 24 Jul 2024
Edgestream Partners L.P. Takes $605,000 Position in Axonics, Inc. (NASDAQ:AXNX) - MarketBeat
Sun, 21 Jul 2024
ProShare Advisors LLC Has $880,000 Position in Axonics, Inc. (NASDAQ:AXNX) - American Banking and Market News
Wed, 29 May 2024
Artisan Small Cap Fund Exited Axonics (AXNX) on an Acquisition Announcement - Yahoo Finance
Fri, 22 Mar 2024
Axonics Stockholders Approve Merger Agreement with Boston Scientific - Business Wire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 51 (M) |
Shares Float | 50 (M) |
Held by Insiders | 1 (%) |
Held by Institutions | 86.3 (%) |
Shares Short | 3,400 (K) |
Shares Short P.Month | 3,470 (K) |
EPS | -0.32 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 12.28 |
Profit Margin | -4.2 % |
Operating Margin | -16.8 % |
Return on Assets (ttm) | -0.7 % |
Return on Equity (ttm) | -2.7 % |
Qtrly Rev. Growth | 29.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 7.58 |
EBITDA (p.s.) | 0.1 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -10 (M) |
Levered Free Cash Flow | -7 (M) |
PE Ratio | -220.94 |
PEG Ratio | 4.6 |
Price to Book value | 5.57 |
Price to Sales | 9.02 |
Price to Cash Flow | -333.75 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |